Clinical Trial Update: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) [Phase 3]

View source ↗

Summary

A Phase 3 trial (CAPItello-292) evaluating capivasertib in combination with a CDK4/6 inhibitor and fulvestrant for advanced/metastatic HR+/HER2- breast cancer i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer | Phase 3 | Status: RECRUITING